论文部分内容阅读
目的:观察参麦注射液联合常规西药治疗对慢性肺源性心脏病患者心肺功能及血清学指标的影响。方法:回顾本院102例气阴两虚证慢性肺源性心脏病患者的病例资料,按照随机数字表法分为对照组与观察组各51例。对照组采用强心、利尿及扩张血管等药物治疗,观察组于对照组的治疗基础上联合参麦注射液治疗。观察2组治疗前后肺功能指标[1秒用力呼气容积(FEV1)、最大肺活量(FVC)、1秒用力呼气量占用力肺活量比值(FEV1/FVC)、肺动脉压(PAP)]、心功能指标[舒张早、晚期血流E峰、A峰峰值速度,舒张早、晚期三尖瓣环运动峰值速度Ve、Va]及血清学指标[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)]的变化;记录2组治疗期间的不良反应发生情况。结果:治疗前,2组FEV1、FVC、FEV1/FVC、PAP比较,差异均无统计学意义(P>0.05)。治疗后,2组FEV1、FVC、FEV1/FVC、PAP均较治疗前改善(P<0.05),观察组的4项肺功能指标均优于对照组(P<0.05)。治疗前,2组舒张早、晚期血流E峰、A峰峰值速度,舒张早、晚期三尖瓣环运动峰值速度Ve、Va比较,差异均无统计学意义(P>0.05)。治疗后,2组E峰、Ve均较治疗前升高(P<0.05),A峰、Va均较治疗前下降(P<0.05);观察组的E峰、Ve均高于对照组(P<0.05),A峰、Va均低于对照组(P<0.05)。治疗前,2组IL-6、IL-8、TNF-α水平比较,差异均无统计学意义(P>0.05)。治疗后,2组IL-6、IL-8、TNF-α水平均较治疗前下降(P<0.05),观察组3项血清学指标水平均低于对照组(P<0.05)。结论:采用参麦注射液联合常规西药治疗气阴两虚证慢性肺源性心脏病,可改善患者的心肺功能及血清学指标,且安全性高。
Objective: To observe the effects of Shenmai injection combined with routine western medicine on cardiopulmonary function and serological parameters in patients with chronic cor pulmonale. Methods: The data of 102 cases of chronic pulmonary heart disease with Qi and Yin Deficiency Syndrome in our hospital were retrospectively analyzed. According to the random number table, 51 cases were divided into control group and observation group. Control group with cardiac, diuretic and dilation of blood vessels and other drugs, the observation group in the control group based on the treatment of shenmai injection. The pulmonary function parameters (FEV1, FVC, FEV1 / PAP, PAP) and heart function were observed before and after treatment in two groups. The indexes [diastolic, late peak E peak, peak a peak velocity, diastolic early and late tricuspid annulus peak velocity Ve, Va] and serological parameters [interleukin-6 -8 (IL-8), tumor necrosis factor-α (TNF-α)]. The incidence of adverse reactions in the two groups were recorded. Results: Before treatment, there was no significant difference in FEV1, FVC, FEV1 / FVC and PAP between the two groups (P> 0.05). After treatment, the FEV1, FVC, FEV1 / FVC and PAP in the two groups improved compared with those before treatment (P <0.05). The four indexes of pulmonary function in the observation group were better than those in the control group (P <0.05). Before treatment, there were no significant differences between the two groups (P> 0.05) in early diastolic and late peak E, peak A velocity, early and late tricuspid annulus peak velocity Ve, Va. After treatment, E peak and Ve in both groups were significantly higher than those before treatment (P <0.05), while peak A and Va were lower than those before treatment (P <0.05); E peak and Ve in observation group were higher than those in control group <0.05), A peak, Va were lower than the control group (P <0.05). Before treatment, there was no significant difference in the levels of IL-6, IL-8 and TNF-α between the two groups (P> 0.05). After treatment, the levels of IL-6, IL-8 and TNF-α in the two groups were significantly lower than those before treatment (P <0.05). The serum levels of three serological markers in the observation group were lower than those in the control group (P <0.05). Conclusion: The use of Shenmai injection combined with conventional western medicine in the treatment of chronic pulmonary heart disease with qi and yin deficiency syndrome can improve the cardiopulmonary function and serological markers of patients with high safety.